What was the overall market valuation of the US ischemic stroke market in 2024?

The overall market valuation was $1032.85 Million in 2024. Read More

What is the projected market valuation for the US ischemic stroke market by 2035?

The projected valuation for 2035 is $2391.92 Million. Read More

What is the expected CAGR for the US ischemic stroke market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 7.93%. Read More

What were the market values for the diagnosis segment in 2024?

In 2024, the market values for the diagnosis segment included $200.0 Million for CT, $300.0 Million for MRI, $150.0 Million for Carotid Ultrasound, and $382.85 Million for Cerebral Angiography. Read More

What are the projected market values for the drug class segment by 2035?

By 2035, the projected market values for the drug class segment are expected to be $150.0 Million for Tissue Plasminogen Activator, $300.0 Million for Anticoagulant, $400.0 Million for Antiplatelet, and $182.85 Million for Antihypertensive. Read More

How does the market for Antiplatelet drugs compare to other drug classes in 2024?

In 2024, the market for Antiplatelet drugs was valued at $400.0 Million, making it the highest among the drug classes. Read More

What was the market value for Cerebral Angiography in 2024?

The market value for Cerebral Angiography in 2024 was $382.85 Million. Read More

What is the significance of the projected growth from 2024 to 2035 in the US ischemic stroke market?

The growth from $1032.85 Million in 2024 to $2391.92 Million by 2035 indicates a robust expansion in the market. Read More

What factors might influence the growth of the US ischemic stroke market in the coming years?

Factors influencing growth may include advancements in medical technology, increased awareness of stroke symptoms, and the development of new treatment options. Read More

US Ischemic Stroke Market

Q: Which companies are considered key players in the US ischemic stroke market?

Key players include Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Roche, AstraZeneca, Johnson & Johnson, Sanofi, Novartis, and Pfizer. Read More

ID: MRFR/MED/14512-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

United States Ischemic Stroke Market Research Report: Size, Share, Trend Analysis - Growth & Industry Forecast 2025 To 2035

US Ischemic Stroke Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)7.93%

2024 Market Size$ 1,032.85 Million

2025 Market Size$ 1,114.75 Million

2035 Market Size$ 2,391.92 Million

Key Players

Boehringer Ingelheim

Bristol-Myers Squibb

Genentech

Roche

AstraZeneca

Johnson & Johnson

Trends

Advancements in Treatment Technologies
Focus on Preventive Care
Integration of Telemedicine Solutions

Opportunities

Increased Awareness and Education
Rising Incidence of Ischemic Stroke
Regulatory Support for Innovative Therapies

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Diagnosis (USD Million)
  1. 4.1.1 CT
  2. 4.1.2 MRI
  3. 4.1.3 Carotid Ultrasound
  4. 4.1.4 Cerebral Angiography
2. 4.2 Chemicals and Materials, BY Drug Class (USD Million)
  1. 4.2.1 Tissue Plasminogen Activator
  2. 4.2.2 Anticoagulant
  3. 4.2.3 Antiplatelet
  4. 4.2.4 Antihypertensive
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Boehringer Ingelheim (DE)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Genentech (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Roche (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AstraZeneca (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Johnson & Johnson (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Novartis (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Pfizer (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DIAGNOSIS
3. 6.3 US MARKET ANALYSIS BY DRUG CLASS
4. 6.4 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
5. 6.5 RESEARCH PROCESS OF MRFR
6. 6.6 DRO ANALYSIS OF CHEMICALS AND MATERIALS
7. 6.7 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
8. 6.8 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
9. 6.9 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
10. 6.10 CHEMICALS AND MATERIALS, BY DIAGNOSIS, 2024 (% SHARE)
11. 6.11 CHEMICALS AND MATERIALS, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
12. 6.12 CHEMICALS AND MATERIALS, BY DRUG CLASS, 2024 (% SHARE)
13. 6.13 CHEMICALS AND MATERIALS, BY DRUG CLASS, 2024 TO 2035 (USD Million)
14. 6.14 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.2.2 BY DRUG CLASS, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Ischemic Stroke Market Segmentation

US Ischemic Stroke Market By Diagnosis (USD Million, 2025-2035)

CT
MRI
Carotid Ultrasound
Cerebral Angiography

US Ischemic Stroke Market By Drug Class (USD Million, 2025-2035)

Tissue Plasminogen Activator
Anticoagulant
Antiplatelet
Antihypertensive

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”